We have demonstrated using in vitro cisplatin or TKI‐erlotinib treatment, routinely used in human lung cancer therapy schemes [36, 37], a significant induced overexpressed LncRNA SOX2‐OT level, in contrast with other LncRNAs, such as GLI1‐AS, GAS5, ZEB1‐AS, and UCA1. The gene discussed is UCA1; the disease is lung carcinoma.